Introduction {#Sec1}
============

Peripheral neuropathic pain (pNeP) is a general pain disorder caused by a lesion or disease of the peripheral somatosensory nervous system and occurs frequently with diabetes or following herpes zoster reactivation. The symptoms of pNeP may include numbness, tingling, weakness, and burning, and may lead to more severe events such as higher blood pressure, vomiting, and diarrhea. Postherpetic neuralgia (PHN) is a persistent, debilitating type of pNeP lasting months to years and is the most common complication of herpes zoster. PHN/pNeP severity is a primary predictor of negative health impact, with the more severe patients reporting low levels of health-related quality of life \[[@CR1]\].

China's rapidly aging population portends a coming transition from acute illness as its primary health challenge to chronic diseases \[[@CR2]\], which require long-term, tailored solutions based on individual patient characteristics. It is generally believed that the prevalence of pNeP and PNP will continue to increase globally due to the aging of the population and higher survival rates from conditions that are associated with pNeP (such as cancer, HIV infection, and diabetes) \[[@CR3]\].

Vera-Llonch et al. \[[@CR4]\] developed a 12-week stochastic simulation model to examine the treatment of pNeP; this work was adapted by Tarride et al. \[[@CR5]\] into a cost-effectiveness model comparing pregabalin versus gabapentin in the management of diabetic peripheral neuropathy (DPN) and PHN in a Canadian setting. Compared to gabapentin, pregabalin was projected to result in 6 and 9 additional days with no or mild pain, and 0.005 and 0.009 quality-adjusted life years (QALYs), for patients with DPN and PHN, respectively. The adapted Canadian model utilized a global perspective to facilitate future adaptations to the healthcare perspectives of additional countries.

Although the cost-effectiveness of pregabalin has previously been assessed in the UK \[[@CR6]\] and Spain \[[@CR7]\], no comparable studies to date have assessed the costs and health impacts for China. The objective of this study was to assess the cost-effectiveness of pregabalin compared with gabapentin in pNeP and PHN from a Chinese healthcare perspective using a China-localized adaptation of the Tarride et al. \[[@CR5]\] model.

Methods {#Sec2}
=======

Approach {#Sec3}
--------

We adapted the Tarride et al. \[[@CR5]\] decision model to evaluate the short-term incremental cost-effectiveness of pregabalin versus gabapentin in China \[[@CR8]\]. The analysis was conducted from a Chinese health system perspective using a 12-week time horizon based on duration of follow-up in the pregabalin clinical trials \[[@CR9], [@CR10]\]. Treatment strategies included pregabalin and generic gabapentin, with the goal of treatment being to reduce daily pain severity. China-specific alterations to the Tarride et al. \[[@CR5]\] model included resource utilization rates, resource costs, drug costs, treatment pathways, and mortality. Due to the short 12-week time horizon, we excluded costs and outcomes discounting, as well as consideration of QALYs and thus incremental cost-effectiveness ratios (ICERs). The decision to exclude the ICER also stems from a World Health Organization suggestion that gross domestic product-based willingness-to-pay per QALY thresholds in developing countries such as China are imperfect and should consider the relevant context of other available public health options, healthcare budgets, and the role of decision makers \[[@CR11]\]. All costs are presented in 2015 US dollars and were converted using an exchange rate of 6.07 RMB = 1 USD. The model was programmed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA).

Model Structure {#Sec4}
---------------

We utilized a three-state (severe, moderate, or no pain) Markov model (Fig. [1](#Fig1){ref-type="fig"}) to represent variable pain scores and associated health state utilities and costs, with a cycle length of 1 day. For any given patient, pain was assumed to vary daily, thus patients could move from one state to another with each cycle. Patient resource use was calculated using a decision analytic model (Fig. [2](#Fig2){ref-type="fig"}) based on the probability of a general practitioner visit followed by subsequent probabilities for additional resources.Fig. 1Markov model structure. The Markov model structure consists of three health states: no pain or mild pain; moderate pain; and severe pain. Pain scores determine these health states, which each have individual utilities and probabilities of resource utilization and costs attachedFig. 2Resource utilization decision tree. A probability of a doctor's visit is assigned to patients in each health state, patients then have probabilities of consuming additional resources and costs if they visit a doctor. *GP* general practitioner

Model Outcomes {#Sec5}
--------------

The primary model outcomes were: (1) post-treatment pain score, (2) total number of days with no or mild pain, (3) drug costs, and (4) total medical-care services costs. Secondary outcomes included: (1) mean number of days with 30%, 40% and 50% reduction in pain scores, (2) mean number of days ≥2 or 3 point reduction in pain, and (3) cost per additional day with no or mild pain. Pain was measured on an 11-point numeric pain rating scale (0 = no pain, 10 = severe pain). Severe pain was classified as pain severity from 7 to 10, moderate pain from 4 to 6, and mild pain from 1 to 3.

Population {#Sec6}
----------

We modeled the patient population based on clinical trial data of patients with pNeP which includes patients with both PHN and DPN, and/or PHN. Patients had moderate to severe pain at treatment initiation, and received an average daily dose of 372 mg/day for pregabalin and 2400 mg/day for gabapentin, although dosage was modifiable through scenario analysis. Patient pain was assumed to be intractable to therapies for underlying conditions.

Model Parameters {#Sec7}
----------------

The model includes data from a variety of sources including physician surveys, randomized clinical trials, and published literature. We identified China-localized model parameters through literature review and a questionnaire of eleven key opinion leaders (Chinese specialists and general practitioners), who provided estimates of initial pain scores specific to the Chinese pNeP and PHN patient populations (Table [1](#Tab1){ref-type="table"}). Efficacy estimates (Table [2](#Tab2){ref-type="table"}) were obtained from published literature and were modeled for each week as the percentage reduction in baseline pain score \[[@CR1]\]: pregabalin efficacy in pNeP was taken from Protocol 1008-155 \[[@CR9]\] and has been used previously \[[@CR4]\]; gabapentin efficacy in pNeP was taken from the pooled analysis of two randomized clinical trials \[[@CR12], [@CR13]\].Table 1Pre-treatment pain scoresScorepNeP (%)PHN (%)4.0 to \<5.018.008.895.0 to \<6.018.1815.336.0 to \<7.019.2719.117.0 to \<8.019.5518.898.0 to \<9.016.3623.339.0 to 10.08.6414.44The pre-treatment pain score distributions were sourced from the physician survey. The distribution shows the percentage of patients within each pain score threshold for both the pNeP and PHN populations*pNeP* peripheral neuropathic pain, *PHN* postherpetic neuralgiaTable 2Weekly percentage reduction in pain scoreWeekPeripheral neuropathic painPostherpetic neuralgiaPregabalin (%)Gabapentin 2400 mg (%)Pregabalin (%)Gabapentin 2400 mg (%)113.717.214.717.3223.224.223.324.9329.927.529.529.2439.129.940.331.2544.431.546.632.7644.232.743.933.7745.033.643.934.5846.334.245.135.0949.834.649.135.41051.134.950.635.71153.335.257.535.91254.135.358.236.0The weekly percentage reductions in pain score are shown for each week of the model for both medications and populations. These percentages contribute to the transition probabilities within the Markov model

The probability of a doctor visit was unique to a patient's pain score on any given week and reflected results from the key opinion leader survey (Table [3](#Tab3){ref-type="table"}). Patients who visited a doctor utilized healthcare resources according to results from the survey (Table [4](#Tab4){ref-type="table"}). Drug costs included the cost of pregabalin and gabapentin (Table [5](#Tab5){ref-type="table"}). The cost of pregabalin was based on the average trial dose of 372 mg per day.Table 3Probability of a doctor visit according to physician surveyHealth stateProbability (%)Mild pain (0.0 to \<4.0)8.89Moderate pain (4.0 to \<7.0)15.33Severe pain (7.0 to \<10.0)19.11Table 4Resource utilizationResourceProbabilityCost per unitNumber of unitsDoctor visitSee Table [3](#Tab3){ref-type="table"}\$52.721Computed tomography (CT Scan)0.231\$55.191Magnetic resonance imaging (MRI)0.23222\$131.141Nerve conduction studies0.415\$41.521Quantitative sensory testing0.485\$21.971Doppler sonograph0.121111\$27.181Electromyography (EMG)0.44090\$47.121Transcutaneous electronic nerve stimulation0.16857\$27.801Implantation of spinal stimulator0.018\$20,5601Physical therapy0.538888\$27.412Nerve block0.526666\$135.421.33333Resource utilization probabilities and costs were sourced from the physician survey. The probability of a doctor's visit was based on the patient's health state (Table [3](#Tab3){ref-type="table"}). The probabilities of the other resources being utilized were assigned to patients who visited the doctorTable 5Drug costsInput (average daily dose)Cost per daySourcePregabalin (372 mg/day)^a^\$8.32Pfizer, data on fileGabapentin (2400 mg/day)\$2.96Pfizer, data on file^a^The average dose of pregabalin was 372 mg per day

Assumptions {#Sec8}
-----------

We assumed clinical management was similar for PHN and DPN patients. Adverse events were not included in the model because no clinically relevant differences exist between pregabalin and gabapentin within the 12-week time horizon. Rates of therapy discontinuation due to adverse events or lack of efficacy were also assumed to be the same between therapies. We assumed primary care providers clinically managed all patients, and that the likelihood that patients will visit their primary care provider in a given week was a function of average level of pain. The efficacy of additional healthcare services is unknown, particularly if used in conjunction with pregabalin or other pharmacotherapy, thus we did not assign health benefits to them.

Analysis {#Sec9}
--------

The 12-week model was designed to estimate the impact of pharmacotherapy on daily pain experience using Bayesian simulation techniques to estimate patients' daily pain experience (measured on 0--10 scale) over time. The expected mean reductions (vs. baseline) in average daily pain scores for therapies of interest were applied to each patient's daily pain scores on a weekly basis to generate expected daily pain scores with treatment. We calculated various summary measures of patient outcomes based on expected daily pain scores for each treatment of interest. Summary measures of the outcomes were combined with utilization of healthcare services, costs of care, and health state utilities to calculate the cost-effectiveness of pregabalin versus gabapentin. We explored parameter uncertainty using a probabilistic sensitivity analysis of 1000 simulations of 1000 patients each, and calculated the mean and 95% credible interval for each model outcome.

Compliance with Ethics Guidelines {#Sec10}
---------------------------------

This analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec11}
=======

The results of the pNeP and PHN analyses are summarized in Table [6](#Tab6){ref-type="table"}. The mean pre-treatment pain scores were 6.7 for patients with pNeP and 7.2 for patients with PHN. At 12 weeks post-treatment initiation, the mean pain scores for the pNeP population were 3.9 and 4.5 for those treated with pregabalin and gabapentin, respectively. In the PHN population, 12-week mean pain scores were 4.2 and 4.9 for patients treated with pregabalin and gabapentin, respectively. Treatment with pregabalin resulted in an additional decrease of 0.6 and 0.7 when compared to patients receiving gabapentin in the pNeP and PHN populations, respectively.Table 6Model outcomesOutcomespNePPHNPregabalinGabapentinDifferencePregabalinGabapentinDifferencePre-treatment pain score6.7 (0)6.7 (0)0 (0)7.2 (0)7.2 (0)0 (0)Post-treatment pain score3.9 (0.02)4.5 (0.02)−0.6 (0.03)4.2 (0.02)4.9 (0.02)−0.7 (0.03)Days no/mild pain40.1 (0.3)30.5 (0.3)9.5 (0.42)35.5 (0.32)25.9 (0.30)9.6 (0.44)Days moderate pain30.2 (0.3)36.3 (0.32)−6.1 (0.44)31.3 (0.32)36.8 (0.32)−5.5 (0.46)Days severe pain13.7 (0.23)17.2 (0.25)−3.5 (0.34)17.2 (0.25)21.3 (0.27)−4.1 (0.37)Days ≥30% reduction50.9 (0.34)42.6 (0.36)8.3 (0.5)50.6 (0.33)42.8 (0.36)7.8 (0.48)Days ≥40% reduction44.4 (0.34)34.7 (0.35)9.7 (0.47)43.3 (0.34)34.1 (0.35)9.2 (0.47)Days ≥50% reduction37.5 (0.34)26.7 (0.33)10.8 (0.46)36.3 (0.34)26.1 (0.33)10.2 (0.46)Days ≥2-point reduction56.2 (0.32)49.3 (0.36)6.9 (0.49)57.4 (0.33)51.2 (0.35)6.2 (0.48)Days ≥3-point reduction42.2 (0.34)32.8 (0.33)9.4 (0.47)44.4 (0.33)35.8 (0.34)8.6 (0.46)Drug costs\$685 (\$0)\$243 (\$0)\$441 (\$0)\$685 (\$0)\$243 (\$0)\$441 (\$0)Non-drug costs\$731 (\$88.79)\$745 (\$89.16)−\$15 (\$121.86)\$742 (\$89.75)\$755 (\$88.27)−\$13 (\$120.98)Total costs\$1415 (\$88.81)\$989 (\$89.36)\$427 (\$122.27)\$1427 (\$89.74)\$998 (\$88.07)\$429 (\$120.97)The model outcomes for both the pNeP and PHN patient populations are presented as the mean (standard deviation) result of each simulation*pNeP* peripheral neuropathic pain, *PHN* postherpetic neuralgia

In the pNeP population, pregabalin resulted in an increase of 9.5 days of no or mild pain, a decrease of −6.1 days of moderate pain, and a decrease of −3.5 days of severe pain compared to gabapentin. Pregabalin had more mean days with a ≥30% (8.3 days), 40% (9.7 days), and 50% reduction (10.8 days) in pain when compared with gabapentin. In the PHN population, pregabalin resulted in an increase of 9.6 days of no or mild pain, a decrease of −5.5 days of moderate pain, and a decrease of −4.1 days of severe pain compared to gabapentin. Pregabalin had more mean days with a ≥30% (7.8 days), 40% (9.2 days), and 50% reduction (10.2 days) in pain when compared with gabapentin.

The cost per additional day of mild/no pain was calculated for both patient populations (Tables [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}). The total costs were higher in both populations in patients treated with pregabalin. In pNeP patient pregabalin resulted in an additional \$427 in total costs when compared with gabapentin. For the PHN population, total costs were an additional \$429 for pregabalin treatment compared to gabapentin.Table 7Cost per additional day of mild/no painVariablePregabalinGabapentinDifferenceDays of mild/no pain40.06 (39.46--40.67)30.52 (29.90--31.11)9.53 (8.74--10.34)Total costs\$1415 (\$1253--\$1599)\$989 (\$821--\$1169)\$427 (\$199--\$678)Cost per day of mild/no pain\$44.74 (\$20.96--\$71.91)The results of the peripheral neuropathic pain population analysis are shown. The results are presented as the mean (95% confidence interval) of the simulationsTable 8Cost per additional day of mild/no painVariablePregabalinGabapentinDifferenceDays of mild/no pain35.50 (34.86--36.12)25.91 (25.35--26.50)9.59 (8.71--10.44)Total costs\$1427 (\$1257--\$1612)\$998 (\$830--\$1180)\$429 (\$203--\$692)Cost per day of mild/no pain\$44.69 (\$20.92--\$71.91)The results of the postherpetic neuralgia population analysis are shown. The results are presented as the mean (95% confidence interval) of the simulations

In both populations, pregabalin treatment resulted in more additional days on mild/no pain and higher costs. In the pNeP patient population, treatment with pregabalin resulted in 9.5 additional days of mild/no pain at an additional cost of \$427, resulting in an incremental cost per additional day of mild/no pain of \$44.69. In the PHN patient population, treatment with pregabalin had 9.6 additional days of mild/no pain at \$429 additional cost, resulting in an incremental cost per additional day of mild/no pain of \$44.74.

Discussion {#Sec12}
==========

We developed a China-localized decision model to determine the cost-effectiveness of pregabalin compared with gabapentin in pNeP and PHN patient populations. We found that treatment with pregabalin leads to decreases in pain scores of 0.6 (pNeP) and 0.7 (PHN) when compared to patients receiving gabapentin, at an incremental cost per additional day of mild/no pain of \$45. Treatment with pregabalin provided 9.5 and 9.6 additional days of mild/no pain and in the pNeP and PHN patient populations, respectively, suggesting that substantial improvements in patient quality of life are possible for these patient populations. Our results were robust to variation in model parameters in probabilistic sensitivity analysis.

pNeP represents a broad class of neuropathies associated with high pain levels, low utility scores, poor sleep, depression, and anxiety, though not on survival. Adding to this complexity, approximately half of pNeP patients are satisfied overall with their current pain medication \[[@CR14]\]. Therefore, it is imperative to make more treatment options available to patients, so that a multifaceted approach to treatment is possible for each unique expression of patient pain. Given the increasing societal burden of these chronic diseases in China, government payers may need to increase coverage for effective treatments such as pregabalin. This will provide the necessary access to the medications that can improve quality of life and thus, potentially, increase productivity and output for the economy.

Randomized, placebo-controlled clinical trials have shown that pregabalin provides statistically and clinically significant improvements in pNeP associated with DPN and PHN \[[@CR15]--[@CR19]\]. The results of our modeling study are similar to the previous Canadian setting adaptation (6 and 9 additional days with no or mild pain for patients with DPN and PHN, respectively). However, our model differed from this previous model by excluding consideration of QALYs because of the perceived limitations imposed by the short time horizon of our model. Furthermore, there has been a shift toward alternative metrics of pNeP health outcomes because clinicians are increasingly appreciating outcomes reduction, such as clinical cure, days with no pain, and glycated hemoglobin (HbA1c), because of the ease of measurement and explanation to patients \[[@CR20]--[@CR22]\]. Lastly, we recognize that the QALY may not be the measure of choice for the Chinese health system, and that pain-free days are more likely to have buy-in from patients and clinicians alike.

Our model had several other limitations worth noting. First, we limited the time horizon to a 12-week period of follow-up based on available trial data; pain in patients with peripheral neuropathies may last for much longer. Second, we did not consider adverse events in our model because we assumed adverse event rates and rates of discontinuation due to adverse events were similar for both treatment populations, primarily because of the short time horizon chosen for the model. In a longer-term model, these rates would be expected to exhibit differences. Third, patients who were referred to specialists were assumed to have received additional healthcare services, which may have had an impact on the costs associated with any given treatment strategy.

Fourth, the model was primarily based on randomized clinical trial data of predominantly white patients that may not represent the real treatment effects, heterogeneity, and drug adherence in a Chinese setting. If China-specific clinical trial data were available we would have used it instead; nonetheless, clinical trial evidence is the gold standard of evidence for decision modeling studies, and while the populations studied may be highly specific, the data produced in the trials is of greater accuracy and credibility than educated guesses. The incorporation of data from other studies may provide different estimates than those we have calculated; however, we believe the parameters selected for this model represent the best available evidence. Lastly, we chose to omit the standard ICER measure of cost-effectiveness because the model's time horizon is brief at only 12 weeks, and because pNeP/PHN is not a fatal condition, thus any assessment of survival and quality-adjusted survival is inherently limited. In lieu of an ICER, the cost per day of no/mild pain is a plain language representation of value that may be of greater use in the Chinese healthcare setting.

Conclusions {#Sec13}
===========

Pregabalin appears to be an effective treatment for PHN and pNeP at an incremental cost per additional day of mild/no pain of \$45, leading to improved outcomes including lower pain scores and an increase in days with no or mild pain, in a Chinese setting. Adding pregabalin to the treatment paradigm for pNeP/PHN would provide physicians with an additional weapon to treat patients with pNeP/PHN that provides a great value.

**Enhanced content** To view enhanced content for this article go to <http://www.medengine.com/Redeem/8844F0603330AAEA>.
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